News & Investors

Want to stay updated? Subscribe to our newsletters. For free.

Have questions? Our live support would be happy to help you.

Year: 2015

Epigenomics AG: Bondholders resolve on amendment of the terms and conditions of the 2013 Convertible Bonds:

PDF 146 KB   Extension of the Term until December 31, 2016 Amendment of the Anti-Dilution Protection Berlin (Germany) and Germantown, MD (U.S.A.), December 18, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, publishes the voting results of the taking of votes without a meeting pursuant to […]

Read more

Epigenomics AG appeals recent FDA request for additional information

PDF 146 KB Berlin (Germany) and Germantown, MD (U.S.A.), November 26, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced that after discussions with FDA in relation to its premarket approval (PMA) application for the Company’s blood-based colorectal cancer (CRC) screening test Epi proColon®, it is […]

Read more

Epigenomics AG appeals recent FDA request for additional information

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 154 KB Epigenomics AG appeals recent FDA request for additional information Berlin, Germany, November 25, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) the German-American cancer molecular diagnostics company, today announced that after discussions with FDA in […]

Read more

Epigenomics AG Announces 2015 Third Quarter and Nine Month Financial Results and Reports on Operational Highlights

PDF 160 KB   Berlin (Germany) and Germantown, MD (U.S.A.), November 18, 2015 – Epigenomics AG (Frankfurt Prime Standard: ECX, OTCQX: EPGNY), the German-American cancer molecular diagnostics company, today announced its financial results for the third quarter and the nine months 2015 ending September 30. Q3 2015 revenue increased by 66% compared to Q3 2014 […]

Read more

Epigenomics AG: Novel panel of blood-based DNA methylation biomarkers shows promising results in the detection of lung cancer

PDF 512 KB Epigenomics’ DNA methylation biomarkers demonstrate high sensitivity compared to commonly used protein biomarkers Being developed as a blood-based test for early lung cancer detection and treatment monitoring Initial results presented at the Association for Molecular Pathology (AMP) 2015 Annual Meeting   Berlin (Germany) and Germantown, MD (U.S.A.), November 9, 2015 – Epigenomics […]

Read more

Epigenomics adjusts 2015 outlook after FDA response letter

Ad hoc Releases 2016 Pursuant to § 15 WpHG (German Securities Trading Act) PDF 74 KB Berlin, Germany, November 4, 2015 – Epigenomics AG, Berlin, Germany, (Frankfurt Prime Standard: ECX; ISIN: DE000A11QW50) adjusts its financial outlook for fiscal year 2015 following the FDA response letter on the Company’s lead product Epi proColon®. As communicated in […]

Read more